eligibility_summary
CD19/CD20+ large B-cell lymphoma (DLBCL NOS, PMBCL, HGBL, transformed FL) relapsed/refractory after anthracycline + anti-CD20. Consent required. Must be eligible for CAR-T + glofitamab, ≥1 high-risk factor (extranodal, tumor >4 cm, TP53 mutation), ECOG 0–2, life ≥12 wks, adequate blood/organ function. Exclude: hypersensitivity, prior allo-SCT or anti-CD19 CAR-T, active HBV/HCV, uncontrolled infection/cardio-cerebrovascular/autoimmune/coagulopathy, HIV, recent malignancy, pregnancy, other serious conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in relapsed/refractory large B‑cell lymphoma testing: 1) Autologous anti‑CD19 CAR T‑cell therapy (gene‑modified T cells) that recognize CD19 and kill B‑cell lymphoma via T‑cell activation and cytotoxicity, 2) Glofitamab, an IgG bispecific T‑cell engager (CD20×CD3, 2:1) that binds CD20 on B cells and CD3 on T cells to redirect T‑cell killing, 3) Obinutuzumab, a glycoengineered type II anti‑CD20 monoclonal antibody used as pre‑treatment to deplete B cells and reduce CRS before glofitamab. Lymphodepleting fludarabine/cyclophosphamide precedes CAR T. Targets/pathways: CD19 on malignant B cells, CD20 on B cells, CD3/TCR signaling on T cells, cytotoxic pathways (perforin/granzyme, ADCC/ADCP).